SCHEMBL2853911

SCHEMBL2853911

NC1CC(=O)N(CCO)C1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
BRD4 O60885 2/20 0.35
CYP19A1 P11511 3/20 0.35
ALDH1A1 P00352 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HTT P42858 2/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
AADAT Q8N5Z0 3/20 0.33
TSHR P16473 2/20 0.33
GOT1 P17174 1/20 0.33
USP2 O75604 1/20 0.33
HSD17B10 Q99714 1/20 0.33
KYAT1 Q16773 1/20 0.33
KYAT3 Q6YP21 1/20 0.33
CYP3A4 P08684 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2853909 1.00 LMNA (0.36) LMNAKDM4EBRD4CYP19A1ALDH1A1
Bromide SCHEMBL20548193 0.98 LMNA (0.35) LMNAKDM4EBRD4CYP19A1ALDH1A1
SCHEMBL18471609 0.82 CYP19A1 (0.36) CYP19A1ALDH1A1SMN1; SMN2HTTTP53
SCHEMBL14275616 0.80 CYP19A1 (0.53) CYP19A1ALDH1A1SMN1; SMN2HTTTP53
SCHEMBL21450546 0.78 CYP19A1 (0.35) BRD4CYP19A1ALDH1A1HTTTP53
SCHEMBL22815230 0.76 ADAM17 (0.36) LMNAKDM4EBRD4CYP19A1SMN1; SMN2
SCHEMBL13071576 0.76 BRD4 (0.39) LMNAKDM4EBRD4CYP19A1ALDH1A1
SCHEMBL24624701 0.76 CYP19A1 (0.36) CYP19A1ALDH1A1SMN1; SMN2HTTTP53
SCHEMBL2687595 0.76 GAA (0.38) LMNACYP19A1ALDH1A1SMN1; SMN2HTT
SCHEMBL2848946 0.76 GAA (0.38) LMNACYP19A1ALDH1A1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144768-A1 KINASE INHIBITOR COMPOUNDS COMPASS HORIZON FUNDING COMPANY LLC 2010-06-10 US claimed
EP-2166857-A1 KINASE INHIBITOR COMPOUNDS Xcovery, INC. (US) 2010-03-31 EP claimed
WO-2008153942-A1 KINASE INHIBITOR COMPOUNDS XCOVERY, INC. (US) 2008-12-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144768-A1 KINASE INHIBITOR COMPOUNDS MAP3K9, MAP3K1, MAP3K8 LMNA 3361/4885KDM4E 1198/4885BRD4 622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.